

GESAMTVERZEICHNIS

1

21.10.2020

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

Moorkens, E.; Barcina Lacosta, T.; Vulto, A.; Schulz, M.; Gradl, G.; Enners, S.; Selke, G.; Huys, I.; Simoens, S.

Pharmaceuticals 2020, 13, 324
doi:10.3390/ph13100324

[Link zur Publikation](#)

Conflicts of interest: S.S., I.H. and A.G.V. have founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). S.S. was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with A.G.V. and I.H.), Celltrion, Mundipharma and Pfizer, and he has had speaking engagements for Amgen and Sandoz. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, a.o. AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Sandoz. E.M., T.B.L., G.G., S.E., M.S. and G.S. declare no conflict of interest.

2

19.10.2020

Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany

Rudolph, U.; Enners, S.; Kieble, M.; Mahfoud, F.; Böhm, M.; Laufs, U.; Schulz, M.

J Hum Hypertens, 14.10.2020
doi.org/10.1038/s41371-020-00425-z

Conflicts of interest: UR has received scientific support and speaker honoraria from Bayer, Berlin Chemie, and Bristol Myers Squibb, all outside the submitted work. FM is supported by Deutsche Gesellschaft für Kardiologie (DGK) and has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic, and ReCor Medical, all outside the submitted work. FM and MB are supported by the Deutsche Forschungsgemeinschaft (SFB TRR219). UL has received speaker honoraria from Bayer, Boehringer Ingelheim, Novartis and Servier, all outside the submitted work. MS has received speaker honoraria from Novartis and Sanofi, all outside the submitted work. All other authors declare no conflict of interest.

3

08.10.2020

“Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription

Mahfoud, F.; Kieble, M.; Enners, S.; Werning, J.; Laufs, U.; Millenaar, D.; Böhm, M.; Kintscher, U.; Schulz, M.

Dtsch Arztebl Int 2020; 117: 687–8.
DOI: 10.3238/arztebl.2020.0687

[Link zur Publikation](#)

Conflicts of interest: Felix Mahfoud erhielt Forschungsunterstützung und Vortragshonorare von Medtronic, Recor, Berlin Chemie und Boehringer Ingelheim. Michael Böhm bekam Honorare für Beratertätigkeit von den Firmen Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Servier, Medtronic, Vifor, Novartis und Bristol Myers Squibb. Ulrich Kintscher erhielt Forschungsunterstützung und/oder Vortragshonorare von Bayer, Berlin Chemie, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Sanofi und Servier. Ulrich Laufs hat Vortragshonorare von Bayer, Boehringer Ingelheim, Novartis und Servier erhalten. Martin Schulz bekam Vortragshonorare von Novartis und Sanofi. Die übrigen Autoren erklären, dass kein Interessenkonflikt besteht.

4

21.10.2019

The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.

Hofmann, G.; Gradl, G.; Schulz, M.; Haidinger, G.; Tanew, A.; Weber, B.

J Eur Acad Dermatol Venereol. 2019 Sep 14. doi: 10.1111/jdv.15952

Conflicts of interest: None declared.

5

21.10.2019

Post-mortem analysis of prescription opioids - A follow-up examination by LC-MS/MS with focus on fentanyl

Schönfeld, T.; Heinemann, A.; Schulz, M.; Gradl, G.; Andresen-Streichert, H.; Müller, A.; Iwersen-Bergmann, S.

Forensic Sci Int. 2019 Oct 9;305:109970. doi: 10.1016/j.forsciint.2019.109970


Conflicts of interest: None declared

6

14.12.2018

Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Fixkombinationen von ACE-Hemmern, Angiotensin-II-Rezeptorblockern, Betablockern, Calciumkanalblockern und Diuretika

Kieble, M.; Enners, S.; Schulz, M.

 Fixkombinationen von Antihypertensiva auf dem deutschen Markt_DAPI_Stand 15.11.2018

Conflicts of interest: none declared.

7

28.09.2018

Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

Gradl, G.; Teichert, M.; Kieble, M.; Werning, J.; Schulz, M.

KEYWORDS

ambulatory care, anti-bacterial agents, drug utilization, Germany, Netherlands, pharmacoepidemiology

Pharmacoepidemiol Drug Saf. 2018;1–12. doi: 10.1002/pds.4643

 Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016

Conflicts of interest: None declared

Extemporaneous formulations in Germany - relevance for everyday clinical practice.

Staubach-Renz, P.; Salzmann, S.; Peveling-Oberhag, A.; Weyer, V.; Zimmer, S.; Gradl, G.; Lang, B.

J Dtsch Dermatol Ges. 2018 May;16(5):566-574. doi: 10.1111/ddg.13519.

Conflicts of interest: None declared

In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.

Krüger, K.; Griese-Mammen, N.; Schubert, I.; Kieble, M.; Botermann, L.; Laufs, U.; Kloft, C.; Schulz, M.


Heart Fail Rev - 2018 Jan;23(1):63-71

Conflicts of interest: None declared

Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison

Gradl, G.; Teichert, M.; Kieble, M.; Werning, J.; Schulz, M.

Poster 46th ESCP Symposium on Clinical Pharmacy (Best Poster Award).
Heidelberg, 09.-11.10.2017. Programme and Abstract Book PE007, p. 166
Int. J. Clin. Pharm. 40, 1 (2018) 295.

 ESCP-2017_Poster_PE007_Oral_antibiotics

Conflicts of interest: None declared



Hinweis: Für die Ansicht der PDF Dokumente wird der Acrobat Reader benötigt. Klicken Sie auf die Grafik, um ihn herunterzuladen.